Currently, Lyra Therapeutics Inc [LYRA] is trading at $20.25, up 310.75%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The LYRA shares have gain 341.18% over the last week, with a monthly amount glided 263.23%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lyra Therapeutics Inc [NASDAQ: LYRA] stock has seen the most recent analyst activity on May 07, 2024, when Jefferies downgraded its rating to a Hold and also revised its price target to $0.50 from $10. Previously, H.C. Wainwright downgraded its rating to Neutral on May 07, 2024, and dropped its price target to $2. On May 07, 2024, downgrade downgraded it’s rating to Underperform. William Blair downgraded its rating to a Mkt Perform. H.C. Wainwright started tracking with a Buy rating for this stock on August 31, 2023, and assigned it a price target of $12. In a note dated May 24, 2022, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $15 on this stock.
This stock has fluctuated between a low of $3.81 and a high of $17.20 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $0.5 within the next 12 months. Lyra Therapeutics Inc [NASDAQ: LYRA] shares were valued at $20.25 at the most recent close of the market. An investor can expect a potential drop of -97.53% based on the average LYRA price forecast.
Analyzing the LYRA fundamentals
Trailing Twelve Months sales for Lyra Therapeutics Inc [NASDAQ:LYRA] were 1.19M which represents -65.60% decline. Gross Profit Margin for this corporation currently stands at -10.19% with Operating Profit Margin at -68.92%, Pretax Profit Margin comes in at -67.09%, and Net Profit Margin reading is -67.11%. To continue investigating profitability, this company’s Return on Assets is posted at -1.41, Equity is -4.74 and Total Capital is -1.82. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 8.61.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Lyra Therapeutics Inc [NASDAQ:LYRA] is 2.96. Also, the Quick Ratio is 2.96, while the Cash Ratio stands at 2.77. Considering the valuation of this stock, the price to sales ratio is 22.54, the price to book ratio is 6.89.
Transactions by insiders
Recent insider trading involved Waksal Harlan, Officer, that happened on Apr 25 ’25 when 0.15 million shares were purchased. Officer, Palasis Maria completed a deal on Apr 09 ’25 to buy 39567.0 shares.
